Disclaimer

This presentation contains certain statements that are forward-looking statements. They appear in a number of places throughout this presentation and include statements regarding the intentions, beliefs and/or current expectations of Smiths Group plc (the “Company”) and its subsidiaries (together, the “Group”) and those of their respective officers, directors and employees concerning, amongst other things, the results of operations, financial condition, liquidity, prospects, growth, strategies and the businesses operated by the Group. By their nature, these statements involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and, unless otherwise required by applicable law, the Company undertakes no obligation to update or revise these forward-looking statements. Nothing in this presentation should be construed as a profit forecast. The Company and its directors accept no liability to third parties. This presentation contains brands that are trademarks and are registered and/or otherwise protected in accordance with applicable law.
Introduction

ANDY REYNOLDS SMITH
CHIEF EXECUTIVE
Agenda

Opening remarks & COVID-19
Andy Reynolds Smith

FY20 Interim Results
John Shipsey

Smiths: strong and resilient
Andy Reynolds Smith
Opening remarks

- Good set of results
- Smiths strong and resilient
- Well positioned for long term growth
COVID-19: what we can see today

- Safety of our people
- Managing disruption to maintain supply and service
- Increasing disruption with demand reduction

MAXIMISING BUSINESS CONTINUITY
Prepared for uncertainty

RESILIENT BUSINESS MODEL

John Crane
- c.50% Oil & Gas - negligible upstream exposure
- c.70% aftermarket and service
- Critical facilities and products

Detection
- Passenger airports closing or running at reduced rate
- c. 50% aftermarket
- Governmental and regulatory underpin

Flex-Tek & Interconnect
- Diversified end markets
Smiths Medical

- Sustaining growth and improvement
- Separation delayed due to uncertainty; strategic intent unchanged
- Playing a critical role in the global fight to combat COVID-19

FURTHER GOOD PROGRESS
Interim Results 2020

JOHN SHIPSEY
CHIEF FINANCIAL OFFICER
Further good growth and cash

<table>
<thead>
<tr>
<th></th>
<th>H1 2020</th>
<th>H1 2019</th>
<th>Reported change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Continuing Operations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>1,240</td>
<td>1,143</td>
<td>+8% +3% underlying</td>
</tr>
<tr>
<td>Operating profit</td>
<td>186</td>
<td>175</td>
<td>+6% +1% underlying</td>
</tr>
<tr>
<td>Profit before tax</td>
<td>160</td>
<td>146</td>
<td>+10%</td>
</tr>
<tr>
<td>Operating cash</td>
<td>202</td>
<td>109</td>
<td>+85% Cash conversion 109%</td>
</tr>
<tr>
<td><strong>Discontinued Operations</strong></td>
<td>70</td>
<td>54</td>
<td>+30% Underlying revenue and OP +1%</td>
</tr>
<tr>
<td>Profit after tax</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit for the year</td>
<td>187</td>
<td>160</td>
<td>+17% +3% underlying; +7% including M&amp;A</td>
</tr>
<tr>
<td>Total basic EPS</td>
<td>46.9p</td>
<td>40.2p</td>
<td>+17%</td>
</tr>
<tr>
<td>Free cash-flow</td>
<td>132</td>
<td>71</td>
<td>+86%</td>
</tr>
</tbody>
</table>

1 Headline excludes non operating items as defined in note 3 of the accounts. Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange, acquisitions, and add back depreciation and amortisation of discontinued operations for comparability purposes
2 HY2019 has been restated for Smiths Medical reclassification as discontinued operations
3 Continuing operations exclude Smiths Medical which is accounted for as ‘discontinued operations – businesses held for distribution’, given the intended separation of Smiths Medical
4 Discontinued operations as defined in note 17 to the financial statements
H1 revenue by Division

**John Crane**

- **+6%**
- **£474m**

Continued good growth led by OE

<table>
<thead>
<tr>
<th>Division</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy</td>
<td>+c.11%</td>
</tr>
<tr>
<td>Industrials</td>
<td>c.-(2)%</td>
</tr>
<tr>
<td>OE</td>
<td>+8%</td>
</tr>
<tr>
<td>Aftermarket</td>
<td>+5%</td>
</tr>
</tbody>
</table>

**Smiths Detection**

- **+4%**
- **£378m**

Good growth led by OE

<table>
<thead>
<tr>
<th>Division</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aviation</td>
<td>+5%</td>
</tr>
<tr>
<td>Other Security Systems</td>
<td>+3%</td>
</tr>
<tr>
<td>OE</td>
<td>+8%</td>
</tr>
<tr>
<td>Aftermarket</td>
<td>+1%</td>
</tr>
</tbody>
</table>

**Flex-Tek**

- **+3%**
- **£248m**

Continued growth led by Aerospace

<table>
<thead>
<tr>
<th>Division</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerospace</td>
<td>+5%</td>
</tr>
<tr>
<td>Industrials</td>
<td>+2%</td>
</tr>
</tbody>
</table>

**Smiths Interconnect**

- **(7)%**
- **£140m**

Decline primarily driven by previously communicated market slowdown

---

1 Headline excludes non operating items as defined in note 3 of the accounts. Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange and acquisitions.
## H1 operating profit by Division

<table>
<thead>
<tr>
<th>Division</th>
<th>Operating Profit (OP)</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>JOHN CRANE</strong></td>
<td>£101m</td>
<td>21.3%</td>
</tr>
<tr>
<td>Volume growth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Higher OE mix</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SMITHS DETECTION</strong></td>
<td>£57m</td>
<td>15.0%</td>
</tr>
<tr>
<td>Positive volume growth</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Higher OE mix</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FLEX-TEK</strong></td>
<td>£46m</td>
<td>18.4%</td>
</tr>
<tr>
<td>Continued strong</td>
<td></td>
<td></td>
</tr>
<tr>
<td>performance</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SMITHS INTERCONNECT</strong></td>
<td>£9m (50)%</td>
<td>6.5%</td>
</tr>
<tr>
<td>Lower volumes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Addressing cost base</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growth investment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Headline excludes non operating items as defined in note 3 of the accounts. Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange and acquisitions.
Smiths Medical sustaining growth\(^1\)

<table>
<thead>
<tr>
<th>Revenue</th>
<th>£434m</th>
<th>+1%</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Infusion systems</td>
<td>(3)%</td>
<td></td>
</tr>
<tr>
<td>- Vascular access</td>
<td>+3%</td>
<td></td>
</tr>
<tr>
<td>- Vital Care</td>
<td>+2%</td>
<td></td>
</tr>
</tbody>
</table>

Continuing momentum

<table>
<thead>
<tr>
<th>Operating Profit</th>
<th>£94m</th>
<th>+1%</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Continued strong gross margin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Restructuring and one-off costs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) Headline excludes non operating items as defined in note 3 of the accounts. Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange, acquisitions and supplemental sales for divested businesses, and adds back depreciation and amortisation of discontinued operations.
## Strong operating and free cash-flow

<table>
<thead>
<tr>
<th>£m</th>
<th>H1 2020</th>
<th>H1 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONTINUING OPERATIONS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating profit¹</td>
<td>186</td>
<td>175</td>
</tr>
<tr>
<td>Capex net of depreciation and amortisation</td>
<td>(10)</td>
<td>(3)</td>
</tr>
<tr>
<td>Change in working capital</td>
<td>(2)</td>
<td>(73)</td>
</tr>
<tr>
<td>Other</td>
<td>28</td>
<td>10</td>
</tr>
<tr>
<td>OPERATING CASH-FLOW¹</td>
<td>202</td>
<td>109</td>
</tr>
<tr>
<td>TOTAL GROUP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPERATING CASH-FLOW¹</td>
<td>252</td>
<td>180</td>
</tr>
<tr>
<td>Interest¹</td>
<td>(16)</td>
<td>(25)</td>
</tr>
<tr>
<td>Taxation¹</td>
<td>(60)</td>
<td>(52)</td>
</tr>
<tr>
<td>Pension</td>
<td>(16)</td>
<td>(15)</td>
</tr>
<tr>
<td>Other investment and non-headline</td>
<td>(28)</td>
<td>(17)</td>
</tr>
<tr>
<td>FREE CASH-FLOW</td>
<td>132</td>
<td>71</td>
</tr>
</tbody>
</table>

¹ Headline excludes non operating items as defined in note 3 of the accounts.
Strong well-managed balance sheet

**Pension**
- Two UK plans:
  - Accounting surplus of £486m; overall fully funded on technical provisions basis
  - Over 35% of UK liabilities de-risked through buy-ins
  - 90% of assets in government and investment-grade bonds

**Net debt**
- Net debt of £1.3bn (including £134m of leases)
- Net debt: EBITDA 1.8x\(^1\)
- Average debt maturity is 4.6 years, with no maturities until October 2022
- No covenant obligations on bonds

**Liquidity**
- Cash generative business - track record of ~100% cash conversion
- c.£250m of cash
- Undrawn c.£600m RCF - interest cover covenant
- Liquidity of over £850m
- Based on rating, eligible to access further £600m under CCFF

---

\(^1\) EBITDA is based on 12 months rolling for continuing and discontinued operations. Please refer to note 18 of the accounts for detailed calculation

WELL PLACED TO NAVIGATE THE CURRENT ENVIRONMENT
Smiths – a strong and resilient company

ANDY REYNOLDS SMITH
CHIEF EXECUTIVE
Well-positioned to navigate short-term challenges

- Critical nature of our products and services
- Flexible and resilient operating model
- Financially strong
- Actions to cut costs and preserve cash

PROUD OF OUR PEOPLE
Designed to outperform

- Well-positioned in long term, attractive growth markets
- Highly-differentiated, market-leading products and services
- Organic growth complemented by disciplined M&A
- World-class operational excellence
- A culture of innovation, entrepreneurship and relentless execution

LEADING NOW AND IN THE FUTURE
QUESTIONS & ANSWERS
Good revenue growth\textsuperscript{1,2}

1 Headline excludes non operating items as defined in note 3 of the accounts. Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange and acquisitions.
2 Continuing operations exclude Smiths Medical which is accounted for as ‘discontinued operations – businesses held for distribution to owners’, given the intended separation of Smiths Medical.
3 Includes HY2020 performance from acquisitions that do not have comparators for the prior year.
Operating profit growth complemented by acquisition\(^1,2\)

---

1. Headline excludes non operating items as defined in note 3 of the accounts. Underlying modifies headline performance to: adjust prior year to reflect an equivalent period of ownership for divested businesses; and exclude the effects of foreign exchange and acquisitions.

2. Continuing operations exclude Smiths Medical which is accounted for as ‘discontinued operations – businesses held for distribution to owners’, given the intended separation of Smiths Medical.

3. Includes HY2020 performance from acquisitions that do not have comparators for the prior year.
### Income statement¹

<table>
<thead>
<tr>
<th></th>
<th>H1 2020</th>
<th>H1 2019</th>
<th>Reported change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>1,240</td>
<td>1,143</td>
<td>+8%</td>
</tr>
<tr>
<td><strong>Headline² operating profit</strong></td>
<td>186</td>
<td>175</td>
<td>+6%</td>
</tr>
<tr>
<td>Amortisation of acquisition related intangible assets</td>
<td>(28)</td>
<td>(16)</td>
<td></td>
</tr>
<tr>
<td>Legacy pension scheme arrangements</td>
<td>8</td>
<td>(29)</td>
<td></td>
</tr>
<tr>
<td>Post acquisition integration costs and fair value adjustment unwind</td>
<td>(3)</td>
<td>(5)</td>
<td></td>
</tr>
<tr>
<td>Acquisition and disposal related transaction costs and provision releases</td>
<td>(2)</td>
<td>(2)</td>
<td></td>
</tr>
<tr>
<td>Non-headline litigation provision movements</td>
<td>(16)</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Total non-headline items</strong></td>
<td>(41)</td>
<td>(48)</td>
<td></td>
</tr>
<tr>
<td>Statutory operating profit</td>
<td>145</td>
<td>127</td>
<td>+14%</td>
</tr>
</tbody>
</table>

1  Continuing operations
2  Headline excludes non operating items as defined in note 3 of the accounts
Organic growth: R&D investment$^1$

<table>
<thead>
<tr>
<th>Cash costs</th>
<th>Income statement costs (expensed and amortised)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H1 2020</td>
<td>£62m 5.0% of revenue</td>
</tr>
<tr>
<td>H1 2019</td>
<td>£55m 4.8% of revenue</td>
</tr>
</tbody>
</table>

$^1$ Continuing operations
Total Group - Strong balance sheet

Net debt:EBITDA calculation

- Net debt = £1,270 (as per above)
- EBITDA: 12 months rolling (H1 2020 + H2 2019) for both continuing operations and discontinued operations = £699m

1 For further details please refer to note 18 of the accounts
## ESG external accreditations & metrics

### External recognitions supporting strong ESG fundamentals

<table>
<thead>
<tr>
<th>External recognitions</th>
<th>Score</th>
<th>Environmental</th>
<th>Social</th>
<th>Governance¹</th>
</tr>
</thead>
</table>
| ISS                   |       | ➤ FY2007 to HY2020 reductions  
  • Greenhouse Gas (GHG):  (63)%  
  • Energy: (60)%  
  • Water: (53)%  
  • Non recycle waste: (61)%  
  ➤ Further commitment to reduce our impact on the environment:  
  • 75% renewable electricity commitment by 2040  
  ➤ Technology and innovation as a solution for our customers  
| Governance 1  
Environment 2  
Social 1 |       | ➤ Our People are our most important sources of sustainable competitive advantage:  
  o Safety first (HY2020):  
    • RIR 0.29 (FY2018: 0.39)  
    • LTIR 0.14 (FY2018: 0.17)  
  o Engagement score 73 (FY2018:73) translating into tangible actions to make Smiths a better place to work for  
  ➤ Customers & suppliers  
  o We adhere to our code of business ethics as well as provide regular anti-bribery and corruption training  
|       | ➤ Average tenure on the Board c.3.5 years  
|       | ➤ Diversity of the Board:  
  • Gender (33%)  
  • Ethnicity  
  • Geographies  
|       | ➤ Diverse expertise: MedTech, engineering, automotive, financial services  
|       | ➤ Regular sites visits  

¹ Includes Karin Koenig who joined the Board on April 2nd 2020
COMPETITIVE STRENGTHS
• A strong presence in flow control for rotating equipment
• Strong proprietary technology and expertise in applied engineering
• Broad installed base
• Strong aftermarket service offering with c.200 sales and service centres
• Long-term customer relationships
• Margins at 20%+ through-cycle

GROWTH DRIVERS
• Oil & gas markets recovering driven by underlying energy demand
• Expansion in high-growth markets
• Pent-up demand for maintenance and upgrades in oil & gas and petrochemical
• Need for operational improvements in non-oil and gas process industries
• Disruptive innovations including material science advancements and digital transformation

COMPETITIVE LANDSCAPE
• Competitors range from large multinationals through to small, more focused companies across the product portfolio
• Examples include: Flowserve, EagleBurgmann, Danaher, Hydac, Rexnord

END MARKETS
- c.63% ENERGY
  Mainly downstream exposure
- c.37% INDUSTRIALS
  - Pharmaceutical
  - Chemicals
  - Pulp & paper
  - Water treatment

Revenue
£474m
(38% of Continuing Group)

Headline OP
£101m
(47% of Continuing Group)

Margin
21.3%

ROCE
23.3%

R&D % sales
1.9%

GEOGRAPHIES
- Americas 43%
- Europe 24%
- APAC 19%
- RoW 14%

OE/AM
- Aftermarket 67%
- Original Equipment 33%

JOHN CRANE: Mission-critical solutions for global energy and process industries
SMITHS DETECTION: A global leader in the detection and identification of security threats and contraband

**COMPETITIVE STRENGTHS**
- A global leader with differentiated technologies leveraged across markets
- Significant R&D capability
- Operating in several regulated markets requiring product certification
- Increasing digitisation and aftermarket revenue
- Long-term customer relationships
- Mid-teens + margin through-cycle

**GROWTH DRIVERS**
- Persistent and evolving terror threats
- Changing security regulations for air cargo and passengers
- Growing urbanisation and need to protect people and assets
- Global trade, e-commerce and passengers numbers
- Equipment replacement cycle, typically 7-10 years
- Growth of security infrastructure in emerging markets

**COMPETITIVE LANDSCAPE**
- Competitors range from large multinationals through to small, more focused companies across the product portfolio
- Example include: Nuctech, Rapiscan, L3-SDS

---

**Revenue**
£378m
(30% of Continuing Group)

**Headline OP**
£57m
(27% of Continuing Group)

**Margin**
15.0%

**ROCE**
11.5%

**R&D % sales**
10.5%

---

**GEOGRAPHIES**
- Americas 39%
- Europe 25%
- APAC 23%
- RoW 13%

**OE/AM**
- Original Equipment 52%
- Aftermarket 48%

**END MARKETS**
- Aviation 67%
- Other Security Systems 33%

All figures are based on H1 2020
FLEX-TEK: Innovative components to heat and move fluids and gases

**COMPETITIVE STRENGTHS**
- High-performance products
- Leading capability in design and manufacture
- Increasing pace of innovation
- Strong customer relationships
- Culture, safety and quality
- Mid-teens + margin through-cycle

**GROWTH DRIVERS**
- Steady growth of US housing construction through cycle
- Continued increase in large commercial aircraft production
- International expansion

**COMPETITIVE LANDSCAPE**
- Competitors range from large multinationals through to small, more focused companies across the product portfolio
- Examples include: Parker-Hannifin, Eaton Zoppas and Nibe

<table>
<thead>
<tr>
<th>Revenue</th>
<th>£248m</th>
<th>(20% of Continuing Group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headline OP</td>
<td>£46m</td>
<td>(22% of Continuing Group)</td>
</tr>
<tr>
<td>Margin</td>
<td>18.4%</td>
<td></td>
</tr>
<tr>
<td>ROCE</td>
<td>20.6%</td>
<td></td>
</tr>
<tr>
<td>R&amp;D % sales</td>
<td>0.5%</td>
<td></td>
</tr>
</tbody>
</table>

**GEOGRAPHIES**
- Americas 80%
- Europe 13%
- APAC 6%
- RoW 1%

**OE/AM**
- Original Equipment 59%
- Aftermarket 41%

**END MARKETS**
- Aerospace 31%
- Industrials 69%

All figures are based on H1 2020
**COMPETITIVE STRENGTHS**
- Innovative and technically differentiated offerings
- Ultra-high reliability solutions used in demanding applications
- Strong research and engineering capabilities
- Customer intimacy, responsiveness and product customisation
- Global presence, reach and support
- Mid-teens + margin through-cycle

**GROWTH DRIVERS**
- Increased connectivity
- Growing urbanised population requiring transports and infrastructure
- Increasing geopolitical uncertainty
- Ageing population and rising need for healthcare services

**COMPETITIVE LANDSCAPE**
- Competitors range from large multinationals through to small, more focused companies across the product portfolio
- Examples include Amphenol, TE Connectivity, Molex

**SMITHS INTERCONNECT: Solutions for high-speed, secure connectivity in demanding applications**

<table>
<thead>
<tr>
<th>Revenue</th>
<th>£140m</th>
<th>(11% of Continuing Group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headline OP</td>
<td>£9m</td>
<td>(4% of Continuing Group)</td>
</tr>
<tr>
<td>Margin</td>
<td>6.5%</td>
<td></td>
</tr>
<tr>
<td>ROCE</td>
<td>10.1%</td>
<td></td>
</tr>
<tr>
<td>R&amp;D % sales</td>
<td>8.2%</td>
<td></td>
</tr>
</tbody>
</table>

**GEOGRAPHIES**
- Americas 58%
- Europe 22%
- APAC 16%
- RoW 4%

**OE/AM**
- Original Equipment 97%
- Aftermarket 3%

All figures are based on H1 2020
**COMPETITIVE STRENGTHS**
- Category leader in our chosen markets
- Trusted brands with a reputation for quality and safety
- Strong, defensible intellectual property
- Over 80% of revenue is from single-use devices and proprietary consumables
- Strong customer relationships and extensive global sales network
- Margins 20%+ through-cycle

**GROWTH DRIVERS**
- Ageing populations with increasing personalised healthcare and patient expectation/quality of life
- Increasing incidence of chronic diseases
- Increasing need for connected systems and data analytics
- Growth of alternate site and home-based healthcare
- Growing healthcare spend in developing markets

**COMPETITIVE LANDSCAPE**
- Competitors range from large multinationals through to small, more focused companies across the product portfolio
- Examples include: Medtronic, Becton-Dickinson, Baxter, B Braun

### SMITHS MEDICAL: High-quality, cost-effective medical devices and consumables that are vital to patient care globally

<table>
<thead>
<tr>
<th>Revenue</th>
<th>£434m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headline OP</td>
<td>£94m</td>
</tr>
<tr>
<td>Margin</td>
<td>21.7%</td>
</tr>
<tr>
<td>ROCE</td>
<td>13.2%</td>
</tr>
<tr>
<td>R&amp;D % sales</td>
<td>6.1%</td>
</tr>
<tr>
<td>GEOGRAPHIES</td>
<td></td>
</tr>
<tr>
<td>Americas 57%</td>
<td></td>
</tr>
<tr>
<td>Europe 24%</td>
<td></td>
</tr>
<tr>
<td>APAC 17%</td>
<td></td>
</tr>
<tr>
<td>RoW 2%</td>
<td></td>
</tr>
<tr>
<td>OE/AM</td>
<td></td>
</tr>
<tr>
<td>Consumables 82%</td>
<td></td>
</tr>
<tr>
<td>Original Equipment 18%</td>
<td></td>
</tr>
<tr>
<td>END MARKETS</td>
<td></td>
</tr>
<tr>
<td>Infusion systems 35%</td>
<td></td>
</tr>
<tr>
<td>Vascular access 33%</td>
<td></td>
</tr>
<tr>
<td>Vital Care and Specialty products 32%</td>
<td></td>
</tr>
</tbody>
</table>

All figures are based on H1 2020